Target Name: ZMYM6
NCBI ID: G9204
Review Report on ZMYM6 Target / Biomarker Content of Review Report on ZMYM6 Target / Biomarker
ZMYM6
Other Name(s): Zinc finger, MYM-type containing 6 | ZNF198L4 | Zinc finger protein 258 | MYM | Transposon-derived Buster2 transposase-like protein | ZNF258 | zinc finger protein 258 | zinc finger, BED-type containing 7 | transposon-derived Buster2 transposase-like protein | zinc finger MYM-type containing 6 | Zinc finger MYM-type containing 6 | KIAA1353 | Buster2 | ZMYM6_HUMAN | zinc finger, MYM-type 6 | Zinc finger MYM-type protein 6 | ZBED7

ZMYM6: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes. ZMYM6, a ZFN with 6 conserved Zn finger residues, has been identified as a potential drug target and biomarker in various diseases. In this article, we will discuss the structure, function, and potential therapeutic applications of ZMYM6.

Structure and Function

ZMYM6 is a 21-kDa protein that contains 6 N-terminal Zn finger residues. The ZN finger is a conserved structural motif that is found in various proteins, including transcription factors, DNA-binding proteins, and zinc-finger proteins. ZMYM6 is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells.

Functional studies have shown that ZMYM6 plays a role in various cellular processes, including cell signaling, DNA replication, and apoptosis. ZMYM6 has been shown to interact with various protein partners, including the transcription factor p21 (CDK4), the DNA-binding protein p53, and the tumor suppressor protein p53.

In addition to its role in cellular signaling, ZMYM6 has also been shown to be a potential biomarker for various diseases. For example, ZMYM6 has been shown to be overexpressed in various cancer types, including breast, lung, and colon cancer. Furthermore, high levels of ZMYM6 have been associated with poor prognosis in cancer patients.

Potential Therapeutic Applications

The potential therapeutic applications of ZMYM6 are vast and range from treating cancer to treating cardiovascular diseases. One of the primary goals of cancer treatment is to inhibit the uncontrolled cell growth that is characteristic of cancer cells. ZMYM6 has been shown to be a potential drug target for cancer because of its role in cell signaling.

For example, ZMYM6 has been shown to inhibit the activity of the transcription factor p21 (CDK4), which is a key regulator of cell growth and division. This inhibition of p21 activity has been shown to lead to the growth arrest and apoptosis of cancer cells. Therefore, ZMYM6 could be a useful drug target for cancer treatment.

In addition to its potential cancer therapeutic applications, ZMYM6 has also been shown to have potential applications in treating cardiovascular diseases. The ZN finger is a conserved structural motif that is found in various transcription factors, including the myocardial transcription factor Myb, which is critical for cardiac function.

Studies have shown that ZMYM6 has been expressed in the hearts and that it plays a role in cardiac development and function. Furthermore, high levels of ZMYM6 have been associated with poor cardiac function and increased risk of cardiovascular disease. Therefore, ZMYM6 could be a potential drug target for treating cardiovascular diseases.

Conclusion

In conclusion, ZMYM6 is a ZFN that has been shown to play a role in various cellular processes, including cell signaling and DNA replication. Its function as a potential drug target and biomarker makes it an attractive target for research into the development of new therapies for cancer and cardiovascular diseases. Further studies are needed to fully understand the role of ZMYM6 in these processes and to determine its potential as a drug target.

Protein Name: Zinc Finger MYM-type Containing 6

Functions: Plays a role in the regulation of cell morphology and cytoskeletal organization

The "ZMYM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZMYM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253